RxDoctor Payments Data

Amanda Riley, NP

Family · Butler, GANPI 1992126775

Payments from drug & device makers

$8,763in general payments, 2019–2025

Across 458 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Lilly USA, LLC$941
  • Novartis$543
  • Amgen$522
  • Xeris Pharmaceuticals, Inc.$443
  • Sanofi-aventis U.S. LLC$376
  • plus $4K from 37 others

What the payments were for

  • Food & beverage$8,751100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,763 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$54,658
Medicare patients
199
Services billed
1,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide426$778,720
MounjaroTirzepatide250$309,924
JardianceEmpagliflozin203$223,054
TrulicityDulaglutide68$117,426
Tresiba Flextouch U-200Insulin Degludec105$107,739
FarxigaDapagliflozin Propanediol62$78,784
Soliqua 100-33Insulin Glargine/Lixisenatide42$67,416
Tresiba Flextouch U-100Insulin Degludec84$56,678
RybelsusSemaglutide33$47,607
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog27$45,556
JanuviaSitagliptin Phosphate49$44,126
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/727$29,455
Humulin R U-500 KwikpenInsulin Regular, Human29$22,909
Novolog FlexpenInsulin Aspart56$21,220
TradjentaLinagliptin29$20,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus, Novolog$1,527$832,141475 claims
Lilly USA, LLCMounjaro, Trulicity, Humalog$941$435,617346 claims
Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr$176$262,732245 claims
AstraZenecaFarxiga$249$78,78462 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$376$67,41642 claims
AbbVieSynthroid$150$10,777168 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid$334$3,873225 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.

Other family in Butler

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →